Business
Table 1 (continued)
Buyer Country Target Country Focus/assets Total value Details
Nycomed Switzerland Bradley Pharmaceuticals US dermatology $346 million
Ocimum Biosolutions India Gene Logic’s genomics assets US genomics $10 million
Oncologic US Triton Biosystems US oncology N/A
OPG Netherlands Byram Healthcare US home deliveries $132 million
of medicines
Oriola-KD Finland Vitim, Moron Russia retailer, wholesaler €70-90 million
Otsuka Pharmaceutical Japan Interpharma Praha Czech Republic manufacturing N/A
Paion Germany Cenes Pharmaceuticals UK CNS, thrombotics €13.7 million
Parexel International US ClinPhone UK interactive response $182 million
technology
Perrigo US Galpharm Healthcare UK OTC, prescription $86 million
products
Perrigo US JB Laboratories US OTC, nutritional $44 million
products
Perrigo US Laboratorios Diba Mexico OTC, prescription $25 million
products
Pf_i zer US Coley Pharmaceuticals US vaccines, $164 million
immunomodulatory
drug candidates
Pf_i zer US Covx US oncology, metabolic N/A
diseases
Pf_i zer US Encysive Pharmaceuticals US novel small molecules $195 million
Pf_i zer US Serenex US oncology N/A
Pharmathene US Avecia’s biodefence vaccines UK vaccines $40 million
Phase Forward US Clarix US interactive response $40 million
technology
Phoenix Pharma France France CERP Lorraine’s French France wholesaler N/A
wholesaling business
PSI Russia Thywill Argentina CRO N/A
Reckitt Benckiser UK Adams Respiratory Therapeutics US respiratory $2.3 billion
Recordati Italy Orphan Europe France orphan drugs €135 million
Recordati Italy Fic, Fic Medical France registration, €12 million
promotion of
pharmaceuticals for
third parties in Russia
and CIS
Recordati Italy Yeni Ilac Turkey urology €48 million
Roche Switzerland Piramed UK oncology, $175 million
inf_l ammation
Roche Switzerland Genentech US biotechnology $43.7 billion Roche already
majority
shareholder –
deal ongoing
Roche Switzerland Mirus Bio US RNAi $125 million
Roche Switzerland Arius Research Canada antibodies Cdn$191
million
($188.8 million)
Sanof_i -Aventis France Zentiva Czech Republic generics $1.8 billion deal ongoing
Sanof_i -Aventis France Acambis UK vaccines £285 million
Selvita Poland Biocentrum Poland microbiology N/A
Shionogi Japan Sciele Pharma US generics, cardiovascular, $1.1 billion
diabetes
Shire UK Jerini Germany genetic therapies, other N/A
Siro Clinpharm India Omega Mediation Group Germany CRO N/A
Solvay Pharmaceuticals Belgium Innogenetics Belgium diagnostics €178 million
Strides Arcolab India GenePharm Australasia Australia generics N/A
Sygnis Pharma Germany Amnestix US neurology €4 million
Symyx Technologies US Integrity Biosolution US formulation services N/A
Taisho Japan Biofermin Japan OTC ¥27.3 billion
($256.6 million)
Takeda Japan Amgen’s Japanese subsidiary Japan biologics N/A
Takeda Japan Millennium Pharmaceuticals US oncology $8.8 billion
Teva Pharmaceutical Industries Israel Cogenesys US biopharmaceuticals/ $400 million
biogenerics
Teva Pharmaceutical Industries Israel Bentley Pharmaceuticals Spain generics $360 million
Teva Pharmaceutical Industries Israel Barr Pharmaceuticals US generics $7.5 billion deal ongoing
The Medicines Company US Curacyte Discovery Germany antithrombotics $25 million
TPG Capital (private equity) US Axcan Pharma Canada gastroenterology $1.3 billion
TPG Capital (private equity) US SIA International Russia wholesaler $800 million 50% stake
Uluru US Bio Med Sciences US wound healing $10 million
United Drug Ireland Sharp Corp US packaging $99 million
Valeant Pharmaceuticals US Coria Laboratories US dermatology $95 million
ViroPharma US Lev Pharmaceuticals US hereditary angioedema $443 million
Wuxi Pharmatech China Apptec Laboratory Services US CRO N/A
Zach System Italy PPG Industries’ f_i ne chemicals business US f_i ne chemicals $65 million
Zimmer US Abbott Laboratories’ spine business US spine products $360 million
Zydus Cadila India Laboratorios Combix Spain generics N/A
22
www.scripnews.com/supplements Scrip 100
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128